Physician profile
Dominick Basile
NPI 1366531311
$7,329.86
in general payments reported to CMS, 2019-2025
32 companies · $863 in 2025
The $863 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $831 · 2021: $1,194 · 2022: $1,300 · 2023: $1,259 · 2024: $1,012 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,639.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,007.01 | 2019-2025 | |
| Lilly USA, LLC | $789.16 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $538.01 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $525.79 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $361.58 | 2019-2024 | Xarelto |
| Abbvie INC. | $354.03 | 2021-2023 | Ubrelvy |
| Merck Sharp & Dohme LLC | $342.56 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $251.68 | 2019-2023 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $240.83 | 2019-2022 | |
| Allergan, INC. | $190.41 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $174.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $122.87 | 2019-2022 | |
| Exact Sciences Corporation | $119.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.16 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $63.52 | 2020-2022 | |
| Abbott Laboratories | $58.78 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $55.85 | 2019-2024 | Krystexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $50.94 | 2022 | |
| Phathom Pharmaceuticals, INC. | $50.13 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $40.64 | 2020-2021 | |
| Daiichi Sankyo INC. | $40.58 | 2023 | Injectafer |
| Krystal Biotech INC | $38.41 | 2024 | Vyjuvek |
| Corcept Therapeutics | $21.26 | 2025 | Korlym |
| Vbi Vaccine (Delaware) INC. | $20.72 | 2022 | |
| Althera Pharmaceuticals LLC | $19.95 | 2021 | |
| Sanofi Pasteur INC. | $17.52 | 2019 | |
| Eisai INC. | $16.82 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.75 | 2023 | |
| Scilex Pharmaceuticals INC. | $15.50 | 2019 | |
| Collegium Pharmaceutical, INC. | $15.16 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dominick Basile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.